References
- MoodyDEMetabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphineExpert Opin Drug Metab Toxicol20139667569723537174
- EMCDDAEuropean Drug Report 2014: Trends and Developments Available from: http://www.emcdda.europa.eu/publications/edr/trends-developments/2014Accessed April 19, 2015
- YokellMAZallerNDGreenTCRichJDBuprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international reviewCurr Drug Abuse Rev201141284121466501
- AtluriSSudarshanGManchikantiLAssessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011Pain Physician2014172E119E12824658483
- BöttcherMBeckOEvaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatmentJ Anal Toxicol200529876977616356333
- SalehAStephansonNNGranelliIVillénTBeckOEvaluation of a direct high-capacity target screening approach for urine drug testing using liquid chromatography-time-of-flight mass spectrometryJ Chromatogr B Analyt Technol Biomed Life Sci2012909613
- GeorgeSPosition of immunological techniques in screening in clinical toxicologyClin Chem Lab Med200442111288130915576291
- SaitmanAParkHDFitzgeraldRLFalse-positive interferences of common urine drug screen immunoassays: a reviewJ Anal Toxicol201438738739624986836
- Thermo Fisher ScientificDrugs of Abuse Cross-Reactivity Guide, CEDIA Buprenorphine 5 ng/mL CutoffThermo Fisher Scientific, Clinical DiagnosticsFremont2013 Available from: http://www.thermoscientific.com/content/dam/tfs/SDG/CDD/CDD%20Documents/Product%20Manuals%20&%20Specifications/Diagnostic%20Testing%20Reagents/Drug%20of%20Abuse%20Testing%20(DAT)%20Calibrators%20Controls%20and%20Reagents/Drug%20of%20Abuse%20Reagents/CEDIA-Buprenorphine-5ng-mL-CRG-R14.pdfAccessed April 19, 2015
- MelansonSESnyderMLJarolimPFloodJGA new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuseJ Anal Toxicol201236320120622417836
- PavlicMLibisellerKGrubwieserPRablWCross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?Int J Legal Med2005119637838115834736
- HullMJBiererMFGriggsDALongWHNixonALFloodJGUrinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassayJ Anal Toxicol200832751652118713521
- European UnionOfficial Journal of the European Communities2002 L 221/8. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:221:0008:0036:EN:PDF
- FerraraSDTedeschiLFrisonGDrugs-of-abuse testing in urine: statistical approach and experimental comparison of immunochemical and chromatographic techniquesJ Anal Toxicol19941852782917990448
- BirchMACouchmanLPietromartireSFalse-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpirideJ Anal Toxicol201337423323623471956
- YueQYSvenssonJOAlmCSjöqvistFSäweJInterindividual and interethnic differences in the demethylation and glucuronidation of codeineBr J Clin Pharmacol19892866296372611085
- PoseyBLKimbleSNHigh-performance liquid chromatographic study of codeine, norcodeine, and morphine as indicators of codeine ingestionJ Anal Toxicol19848268746716978
- DelbekeFTDebackereMUrinary concentrations of codeine and morphine after the administration of different codeine preparations in relation to doping analysisJ Pharm Biomed Anal1991910–129599641822219
- YueQYHasselströmJSvenssonJOSäweJPharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquineBr J Clin Pharmacol19913166356421867957